Unichem Laboratories has received an approval for sale and transfer of its business of manufacture, sale, marketing and distribution of domestic formulations in India and Nepal, together with all specified tangible and intangibles assets, contracts, rights, personnel and employees, data and records, inventory and other assets and liabilities as agreed between the parties in relation to the said business (Transferred Business) by way of slump sale on a going concern basis, to Torrent Pharmaceuticals upon terms and conditions contained in the agreements proposed to be entered into by Unichem with Torrent for a total consideration of Rs 3,600 crore, subject to such price adjustments and amendments, if any, as may be agreed between the parties. The board of directors at its meeting held on November 3, 2017 has approved for the same.
The transferred business will include the portfolio of several brands in India and Nepal, manufacturing facility at Sikkim and employees performing work in relation to the transferred business. The above transaction is subject to customary conditions precedent, including, shareholders’ approval and is expected to close in the calendar year 2017. Unichem Laboratories will remain an independent publicly listed company with no change in its existing shareholding.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: